Skip to Content
Merck
All Photos(1)

Key Documents

SAB4300137

Sigma-Aldrich

Anti-phospho-PRKDC (pThr2609) antibody produced in rabbit

affinity isolated antibody

Synonym(s):

Anti-DNA-PKcs antibody produced in rabbit, Anti-DNAPK antibody produced in rabbit, Anti-DNPK1 antibody produced in rabbit, Anti-HYRC antibody produced in rabbit, Anti-protein kinase, DNA-activated, catalytic polypeptide antibody produced in rabbit

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

MDL number:
MFCD01321942
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

Quality Level

100

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

~450 kDa

species reactivity

human

concentration

1 mg/mL

technique(s)

western blot: 1:500-1:1000

isotype

IgG

immunogen sequence

(V-E-TP-Q-A)

NCBI accession no.

NP_001075109.1

UniProt accession no.

P78527

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

phosphorylation (pThr2609)

Gene Information

human ... PRKDC(5591)

Immunogen

Peptide sequence around phosphorylation site of threonine 2609 (V-E-T(p)-Q-A), according to the protein PRKDC.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Target description

The PRKDC gene encodes the catalytic subunit of a nuclear DNA-dependent serine/threonine protein kinase (DNA-PK). The second component is the autoimmune antigen Ku (MIM 152690), which is encoded by the G22P1 gene on chromosome 22q. On its own, the catalytic subunit of DNA-PK is inactive and relies on the G22P1 component to direct it to the DNA and trigger its kinase activity; PRKDC must be bound to DNA to express its catalytic properties.

Physical form

Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Huanrong Ma et al.
International journal of cancer, 142(12), 2578-2588 (2018-01-25)
Cetuximab resistance is a key barrier in treating metastatic colorectal cancer (mCRC). Targeting of metabolic resources import could resensitize drug-resistant cancer cells to anticancer treatments. Here we showed that the expression of the glutamine transporter solute carrier 1 family member
Jessica A Neal et al.
DNA repair, 73, 7-16 (2018-11-10)
DNA-PKcs deficiency has been studied in numerous animal models and cell culture systems. In previous studies of kinase inactivating mutations in cell culture systems, ablation of DNA-PK's catalytic activity results in a cell phenotype that is virtually indistinguishable from that
Changhoon Choi et al.
PloS one, 14(6), e0218049-e0218049 (2019-06-14)
Recent studies have highlighted the implications of genetic variations in the relative biological effectiveness (RBE) of proton beam irradiation over conventional X-ray irradiation. Proton beam radiotherapy is a reasonable radiotherapy option for hepatocellular carcinoma (HCC), but the impact of genetic
Sissel Hauge et al.
Cell cycle (Georgetown, Tex.), 18(8), 834-847 (2019-04-05)
The Wee1 inhibitor MK1775 (AZD1775) is currently being tested in clinical trials for cancer treatment. Here, we show that the p53 target and CDK inhibitor p21 protects against MK1775-induced DNA damage during S-phase. Cancer and normal cells deficient for p21

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service